Drug Type Proteolysis-targeting chimeras |
Synonyms Compound A20 |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H41FN8O6 |
InChIKeyLISIJHJQXVOPKS-VEILYXNESA-N |
CAS Registry2956722-48-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Preclinical | CN | 24 Apr 2024 |